SCHEMBL20818351

SCHEMBL20818351

CC(C)(C)OC(=O)N1CCN(c2c(Br)cn[nH]c2=O)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNH2 Q12809 2/20 0.44
▸ NR1H2 P55055 1/20 0.43
▸ CKS1B P61024 2/20 0.42
▸ SKP1 P63208 2/20 0.42
▸ SKP2 Q13309 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ GPR119 Q8TDV5 2/20 0.41
▸ RET P07949 1/20 0.41
▸ HTT P42858 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ MAPK8 P45983 1/20 0.40
▸ DDB1 Q16531 1/20 0.40
▸ CRBN Q96SW2 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ CHRM2 P08172 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20831279 0.85 CCNC (0.43) NR1H2CKS1BSKP1SKP2MAPT
SCHEMBL20817915 0.84 TRPC5 (0.50) KCNH2NR1H2CKS1BSKP1SKP2
SCHEMBL20818253 0.83 TRPC5 (0.37) NR1H2ALDH1A1SMN1; SMN2CHRM2CHRM4
SCHEMBL25237273 0.80 TRPC5 (0.39) ALDH1A1LMNAMEN1TSHRKMT2A
SCHEMBL11946229 0.79 POLB (0.61) NR1H2CKS1BSKP1SKP2ALDH1A1
SCHEMBL25141629 0.75 PARP1 (0.48) CKS1BSKP1SKP2LMNAHTT
SCHEMBL17634298 0.75 CKS1B (0.45) KCNH2CKS1BSKP1SKP2MAPT
SCHEMBL18502919 0.75 CKS1B (0.46) KCNH2NR1H2CKS1BSKP1SKP2
SCHEMBL20231972 0.75 MAPT (0.49) KCNH2NR1H2CKS1BSKP1SKP2
SCHEMBL25141523 0.74 MAPT (0.48) CKS1BSKP1SKP2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435078-B2 Pyridazinones and methods of use thereof GFB (ABC), LLC (US) 2025-10-07 — — US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 — — US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 — — US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 — — US disclosed
EP-3684364-A2 PYRIDAZINONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2020-07-29 — — EP disclosed
WO-2019055966-A2 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2019-03-21 — — WO disclosed
WO-2019055966-A2 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2019-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF PDXK, ATP6V1B1, REN KCNH2 915/4885NR1H2 1189/4885CKS1B 1285/4885
US-12435078-B2 Pyridazinones and methods of use thereof PDXK, ATP6V1B1, REN KCNH2 915/4885NR1H2 1189/4885CKS1B 1285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback